scispace - formally typeset
G

Gilles Kaplanski

Researcher at Aix-Marseille University

Publications -  210
Citations -  8820

Gilles Kaplanski is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Medicine & Hepatitis C virus. The author has an hindex of 40, co-authored 191 publications receiving 7280 citations. Previous affiliations of Gilles Kaplanski include French Institute of Health and Medical Research & Tufts Medical Center.

Papers
More filters
Journal ArticleDOI

IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation

TL;DR: A surveillance model is proposed: these receptors "keep watch" for both endogenous and exogenous molecules that indicate tissue inquiry, infection and remodeling, and it is suggested that the first Toll-like family receptors that arose in evolution might have acted in both development and immunity by recognizing the degradation of endogenous macromolecules.
Journal ArticleDOI

Interleukin-18 and IL-18 binding protein.

TL;DR: The biology of IL-18 is reviewed as well as its role in human disease, which has been implicated in several autoimmune diseases, myocardial function, emphysema, metabolic syndromes, psoriasis, inflammatory bowel disease, hemophagocytic syndrome, macrophage activation syndrome, sepsis, and acute kidney injury.
Journal ArticleDOI

Interleukin-18: Biological properties and role in disease pathogenesis

TL;DR: There is now ample evidence for a role of IL‐18 in various infectious, metabolic or inflammatory diseases such as influenza virus infection, atheroma, myocardial infarction, chronic obstructive pulmonary disease, or Crohn's disease, however,IL‐18 plays a very specific role in the pathogenesis of hemophagocytic syndromes also termed Macrophage Activation Syndrome.
Journal ArticleDOI

IL-18 induces PD-1-dependent immunosuppression in cancer.

TL;DR: IL-18 is defined as an immunosuppressive cytokine in cancer because it promotes the development of NK-controlled metastases in a PD-1-dependent manner and novel clinical implementations of anti-PD-1 antibodies in human malignancies that produce IL-18 are suggested.